Table S1 Baseline characteristics and receipt of intervention in patients with moderate-high dyspnea scores

Variable	Treatment for dyspnea		
	Treatment received (n=9,040)	No treatment (n=394)	P value
Number of ESAS survey completed, mean \pm SD	10.14±12.67	8.29±11.38	0.004
Age category (at diagnosis) (years), n (%)			0.812
18 to 49	436 (4.8)	14 (3.6)	
50 to 59	1,648 (18.2)	75 (19.0)	
60 to 69	3,000 (33.2)	135 (34.3)	
70 to 79	2,803 (31.0)	120 (30.5)	
80+	1,153 (12.8)	50 (12.7)	
Sex, n (%)			0.72
Female	4,305 (47.6)	184 (46.7)	
Male	4,735 (52.4)	210 (53.3)	
Rural residence (Rurality Index for Ontario 40+), n (%)			<0.001
Major urban	5,897 (65.2)	226 (57.4)	
Non-major urban	2,459 (27.2)	120 (30.5)	
Rural	653 (7.2)	47 (11.9)	
Missing	31 (0.3)	≤5 (0.3)	
Elixhauser comorbidity score (categorical), n (%)			0.102
Less than 4	8,429 (93.2)	359 (91.1)	
4 or more	611 (6.8)	35 (8.9)	
Nearest Census Based Neighbourhood Income Quintile, n (%)			0.004
Q1	1,955 (21.6)	89 (22.6)	
Q2	2,000 (22.1)	110 (27.9)	
Q3	1,773 (19.6)	66 (16.8)	
Q4	1,695 (18.8)	72 (18.3)	
Q5	1,591 (17.6)	53 (13.5)	
Missing	26 (0.3)	≤5 (1.0)	
Deprivation Quintile, n (%)			0.001
Q1	1,616 (17.9)	58 (14.7)	
Q2	1,699 (18.8)	61 (15.5)	
Q3	1,816 (20.1)	73 (18.5)	
Q4	1,878 (20.8)	97 (24.6)	
Q5	1,976 (21.9)	97 (24.6)	
Missing	55 (0.6)	8 (2.0)	
Ethnic Diversity Quintile, n (%)			0.004
Q1	2,045 (22.6)	106 (26.9)	

Table S1 (continued)

Variable	Treatment for dyspnea		
	Treatment received (n=9,040)	No treatment (n=394)	P value
Q2	2,025 (22.4)	89 (22.6)	
Q3	1,728 (19.1)	65 (16.5)	
Q4	1,638 (18.1)	67 (17.0)	
Q5	1,549 (17.1)	59 (15.0)	
Missing	55 (0.6)	8 (2.0)	
Dependency Quintile, n (%)			<0.001
Q1	1,446 (16.0)	41 (10.4)	
Q2	1,601 (17.7)	62 (15.7)	
Q3	1,666 (18.4)	76 (19.3)	
Q4	1,847 (20.4)	97 (24.6)	
Q5	2,425 (26.8)	110 (27.9)	
Missing	55 (0.6)	8 (2.0)	
Instability Quintile, n (%)			0.007
Q1	1,299 (14.4)	54 (13.7)	
Q2	1,568 (17.3)	69 (17.5)	
Q3	1,765 (19.5)	70 (17.8)	
Q4	1,909 (21.1)	98 (24.9)	
Q5	2,444 (27.0)	95 (24.1)	
Missing	55 (0.6)	8 (2.0)	
Year of diagnosis (categorical) , n (%)			0.718
2007 to 2012	3,566 (39.4)	159 (40.4)	
2013 to 2018	5,474 (60.6)	235 (59.6)	
Patients who received systemic therapy after diagnosis, n (%)			0.228
None	3,467 (38.4)	163 (41.4)	
Received therapy	5,573 (61.6)	231 (58.6)	
Died after diagnosis until end of study, n (%)			<0.001
Alive	691 (7.6)	113 (28.7)	
Died during follow-up	8,349 (92.4)	281 (71.3)	
Time from diagnosis to death (months), median (IQR)	8 (4–16)	4 (2–8)	<0.001

ESAS, Edmonton Symptom Assessment System; SD, standard deviation; IQR, interquartile range.